ロード中...
Trastuzumab Sensitizes Ovarian Cancer Cells to EGFR-targeted Therapeutics
BACKGROUND: Early studies have demonstrated comparable levels of HER2/ErbB2 expression in both breast and ovarian cancer. Trastuzumab (Herceptin), a therapeutic monoclonal antibody directed against HER2, is FDA-approved for the treatment of both early and late stage breast cancer. However, clinical...
保存先:
| 主要な著者: | , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
BioMed Central
2010
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2861058/ https://ncbi.nlm.nih.gov/pubmed/20346177 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1757-2215-3-7 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|